Report cover image

Global Progressive Supranuclear Palsy Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 195 Pages
SKU # APRC20361905

Description

Summary

According to APO Research, The global Progressive Supranuclear Palsy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Progressive Supranuclear Palsy include Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Biogen Inc., Bristol Myers Squibb (BMS), AbbVie Inc., Acorda Therapeutics Inc., Teva Pharmaceutical Industries Ltd. and Cortice Biosciences, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Progressive Supranuclear Palsy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Progressive Supranuclear Palsy, also provides the revenue of main regions and countries. Of the upcoming market potential for Progressive Supranuclear Palsy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Progressive Supranuclear Palsy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Progressive Supranuclear Palsy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Progressive Supranuclear Palsy revenue, projected growth trends, production technology, application and end-user industry.

Progressive Supranuclear Palsy Segment by Company

Novartis AG
Merck & Co., Inc.
GlaxoSmithKline plc
Biogen Inc.
Bristol Myers Squibb (BMS)
AbbVie Inc.
Acorda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Cortice Biosciences, Inc.
Aton Pharma, Inc.
AlzProtect SAS
AB Science
Progressive Supranuclear Palsy Segment by Type

Late Stage
Clinical Trial
Early Stage
Others
Progressive Supranuclear Palsy Segment by Application

Clinics
Hospitals
Research Institutes
Others
Progressive Supranuclear Palsy Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Progressive Supranuclear Palsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Progressive Supranuclear Palsy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Progressive Supranuclear Palsy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Progressive Supranuclear Palsy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Progressive Supranuclear Palsy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Progressive Supranuclear Palsy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Progressive Supranuclear Palsy Market by Type
1.2.1 Global Progressive Supranuclear Palsy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Late Stage
1.2.3 Clinical Trial
1.2.4 Early Stage
1.2.5 Others
1.3 Progressive Supranuclear Palsy Market by Application
1.3.1 Global Progressive Supranuclear Palsy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinics
1.3.3 Hospitals
1.3.4 Research Institutes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Progressive Supranuclear Palsy Market Dynamics
2.1 Progressive Supranuclear Palsy Industry Trends
2.2 Progressive Supranuclear Palsy Industry Drivers
2.3 Progressive Supranuclear Palsy Industry Opportunities and Challenges
2.4 Progressive Supranuclear Palsy Industry Restraints
3 Global Growth Perspective
3.1 Global Progressive Supranuclear Palsy Market Perspective (2020-2031)
3.2 Global Progressive Supranuclear Palsy Growth Trends by Region
3.2.1 Global Progressive Supranuclear Palsy Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Progressive Supranuclear Palsy Market Size by Region (2020-2025)
3.2.3 Global Progressive Supranuclear Palsy Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Progressive Supranuclear Palsy Revenue by Players
4.1.1 Global Progressive Supranuclear Palsy Revenue by Players (2020-2025)
4.1.2 Global Progressive Supranuclear Palsy Revenue Market Share by Players (2020-2025)
4.1.3 Global Progressive Supranuclear Palsy Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Progressive Supranuclear Palsy Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Progressive Supranuclear Palsy Key Players Headquarters & Area Served
4.4 Global Progressive Supranuclear Palsy Players, Product Type & Application
4.5 Global Progressive Supranuclear Palsy Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Progressive Supranuclear Palsy Market CR5 and HHI
4.6.3 2024 Progressive Supranuclear Palsy Tier 1, Tier 2, and Tier 3
5 Progressive Supranuclear Palsy Market Size by Type
5.1 Global Progressive Supranuclear Palsy Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Progressive Supranuclear Palsy Revenue by Type (2020-2031)
5.3 Global Progressive Supranuclear Palsy Revenue Market Share by Type (2020-2031)
6 Progressive Supranuclear Palsy Market Size by Application
6.1 Global Progressive Supranuclear Palsy Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Progressive Supranuclear Palsy Revenue by Application (2020-2031)
6.3 Global Progressive Supranuclear Palsy Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Comapny Information
7.1.2 Novartis AG Business Overview
7.1.3 Novartis AG Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.1.4 Novartis AG Progressive Supranuclear Palsy Product Portfolio
7.1.5 Novartis AG Recent Developments
7.2 Merck & Co., Inc.
7.2.1 Merck & Co., Inc. Comapny Information
7.2.2 Merck & Co., Inc. Business Overview
7.2.3 Merck & Co., Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.2.4 Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio
7.2.5 Merck & Co., Inc. Recent Developments
7.3 GlaxoSmithKline plc
7.3.1 GlaxoSmithKline plc Comapny Information
7.3.2 GlaxoSmithKline plc Business Overview
7.3.3 GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.3.4 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio
7.3.5 GlaxoSmithKline plc Recent Developments
7.4 Biogen Inc.
7.4.1 Biogen Inc. Comapny Information
7.4.2 Biogen Inc. Business Overview
7.4.3 Biogen Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.4.4 Biogen Inc. Progressive Supranuclear Palsy Product Portfolio
7.4.5 Biogen Inc. Recent Developments
7.5 Bristol Myers Squibb (BMS)
7.5.1 Bristol Myers Squibb (BMS) Comapny Information
7.5.2 Bristol Myers Squibb (BMS) Business Overview
7.5.3 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.5.4 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio
7.5.5 Bristol Myers Squibb (BMS) Recent Developments
7.6 AbbVie Inc.
7.6.1 AbbVie Inc. Comapny Information
7.6.2 AbbVie Inc. Business Overview
7.6.3 AbbVie Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.6.4 AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio
7.6.5 AbbVie Inc. Recent Developments
7.7 Acorda Therapeutics Inc.
7.7.1 Acorda Therapeutics Inc. Comapny Information
7.7.2 Acorda Therapeutics Inc. Business Overview
7.7.3 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.7.4 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio
7.7.5 Acorda Therapeutics Inc. Recent Developments
7.8 Teva Pharmaceutical Industries Ltd.
7.8.1 Teva Pharmaceutical Industries Ltd. Comapny Information
7.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.8.3 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.8.4 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio
7.8.5 Teva Pharmaceutical Industries Ltd. Recent Developments
7.9 Cortice Biosciences, Inc.
7.9.1 Cortice Biosciences, Inc. Comapny Information
7.9.2 Cortice Biosciences, Inc. Business Overview
7.9.3 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.9.4 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio
7.9.5 Cortice Biosciences, Inc. Recent Developments
7.10 Aton Pharma, Inc.
7.10.1 Aton Pharma, Inc. Comapny Information
7.10.2 Aton Pharma, Inc. Business Overview
7.10.3 Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.10.4 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio
7.10.5 Aton Pharma, Inc. Recent Developments
7.11 AlzProtect SAS
7.11.1 AlzProtect SAS Comapny Information
7.11.2 AlzProtect SAS Business Overview
7.11.3 AlzProtect SAS Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.11.4 AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio
7.11.5 AlzProtect SAS Recent Developments
7.12 AB Science
7.12.1 AB Science Comapny Information
7.12.2 AB Science Business Overview
7.12.3 AB Science Progressive Supranuclear Palsy Revenue and Gross Margin (2020-2025)
7.12.4 AB Science Progressive Supranuclear Palsy Product Portfolio
7.12.5 AB Science Recent Developments
8 North America
8.1 North America Progressive Supranuclear Palsy Revenue (2020-2031)
8.2 North America Progressive Supranuclear Palsy Revenue by Type (2020-2031)
8.2.1 North America Progressive Supranuclear Palsy Revenue by Type (2020-2025)
8.2.2 North America Progressive Supranuclear Palsy Revenue by Type (2026-2031)
8.3 North America Progressive Supranuclear Palsy Revenue Share by Type (2020-2031)
8.4 North America Progressive Supranuclear Palsy Revenue by Application (2020-2031)
8.4.1 North America Progressive Supranuclear Palsy Revenue by Application (2020-2025)
8.4.2 North America Progressive Supranuclear Palsy Revenue by Application (2026-2031)
8.5 North America Progressive Supranuclear Palsy Revenue Share by Application (2020-2031)
8.6 North America Progressive Supranuclear Palsy Revenue by Country
8.6.1 North America Progressive Supranuclear Palsy Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Progressive Supranuclear Palsy Revenue by Country (2020-2025)
8.6.3 North America Progressive Supranuclear Palsy Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Progressive Supranuclear Palsy Revenue (2020-2031)
9.2 Europe Progressive Supranuclear Palsy Revenue by Type (2020-2031)
9.2.1 Europe Progressive Supranuclear Palsy Revenue by Type (2020-2025)
9.2.2 Europe Progressive Supranuclear Palsy Revenue by Type (2026-2031)
9.3 Europe Progressive Supranuclear Palsy Revenue Share by Type (2020-2031)
9.4 Europe Progressive Supranuclear Palsy Revenue by Application (2020-2031)
9.4.1 Europe Progressive Supranuclear Palsy Revenue by Application (2020-2025)
9.4.2 Europe Progressive Supranuclear Palsy Revenue by Application (2026-2031)
9.5 Europe Progressive Supranuclear Palsy Revenue Share by Application (2020-2031)
9.6 Europe Progressive Supranuclear Palsy Revenue by Country
9.6.1 Europe Progressive Supranuclear Palsy Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Progressive Supranuclear Palsy Revenue by Country (2020-2025)
9.6.3 Europe Progressive Supranuclear Palsy Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Progressive Supranuclear Palsy Revenue (2020-2031)
10.2 China Progressive Supranuclear Palsy Revenue by Type (2020-2031)
10.2.1 China Progressive Supranuclear Palsy Revenue by Type (2020-2025)
10.2.2 China Progressive Supranuclear Palsy Revenue by Type (2026-2031)
10.3 China Progressive Supranuclear Palsy Revenue Share by Type (2020-2031)
10.4 China Progressive Supranuclear Palsy Revenue by Application (2020-2031)
10.4.1 China Progressive Supranuclear Palsy Revenue by Application (2020-2025)
10.4.2 China Progressive Supranuclear Palsy Revenue by Application (2026-2031)
10.5 China Progressive Supranuclear Palsy Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Progressive Supranuclear Palsy Revenue (2020-2031)
11.2 Asia Progressive Supranuclear Palsy Revenue by Type (2020-2031)
11.2.1 Asia Progressive Supranuclear Palsy Revenue by Type (2020-2025)
11.2.2 Asia Progressive Supranuclear Palsy Revenue by Type (2026-2031)
11.3 Asia Progressive Supranuclear Palsy Revenue Share by Type (2020-2031)
11.4 Asia Progressive Supranuclear Palsy Revenue by Application (2020-2031)
11.4.1 Asia Progressive Supranuclear Palsy Revenue by Application (2020-2025)
11.4.2 Asia Progressive Supranuclear Palsy Revenue by Application (2026-2031)
11.5 Asia Progressive Supranuclear Palsy Revenue Share by Application (2020-2031)
11.6 Asia Progressive Supranuclear Palsy Revenue by Country
11.6.1 Asia Progressive Supranuclear Palsy Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Progressive Supranuclear Palsy Revenue by Country (2020-2025)
11.6.3 Asia Progressive Supranuclear Palsy Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Progressive Supranuclear Palsy Revenue (2020-2031)
12.2 SAMEA Progressive Supranuclear Palsy Revenue by Type (2020-2031)
12.2.1 SAMEA Progressive Supranuclear Palsy Revenue by Type (2020-2025)
12.2.2 SAMEA Progressive Supranuclear Palsy Revenue by Type (2026-2031)
12.3 SAMEA Progressive Supranuclear Palsy Revenue Share by Type (2020-2031)
12.4 SAMEA Progressive Supranuclear Palsy Revenue by Application (2020-2031)
12.4.1 SAMEA Progressive Supranuclear Palsy Revenue by Application (2020-2025)
12.4.2 SAMEA Progressive Supranuclear Palsy Revenue by Application (2026-2031)
12.5 SAMEA Progressive Supranuclear Palsy Revenue Share by Application (2020-2031)
12.6 SAMEA Progressive Supranuclear Palsy Revenue by Country
12.6.1 SAMEA Progressive Supranuclear Palsy Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Progressive Supranuclear Palsy Revenue by Country (2020-2025)
12.6.3 SAMEA Progressive Supranuclear Palsy Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.